{"drugs":["Delamanid"],"mono":{"0":{"id":"930951-s-0","title":"Generic Names","mono":"Delamanid"},"1":{"id":"930951-s-1","title":"Dosing and Indications","sub":[{"id":"930951-s-1-4","title":"Adult Dosing","mono":"<ul><li>delamanid has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU)<\/li><li><b>Multidrug resistant tuberculosis:<\/b> 100 mg ORALLY twice daily for 24 weeks in combination with an optimized multidrug-resistant TB regimen; continue optimized regimen after the 24-week delamanid treatment period (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"930951-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in patients younger than 18 years "},{"id":"930951-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, mild or moderate:<\/b> no dose adjustment necessary<\/li><li><b>renal impairment, severe:<\/b> use not recommended<\/li><li><b>hepatic impairment, mild:<\/b> no dose adjustment necessary<\/li><li><b>hepatic impairment, moderate to severe:<\/b> use not recommended<\/li><\/ul>"},{"id":"930951-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Multidrug resistant tuberculosis<br\/>"}]},"3":{"id":"930951-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930951-s-3-9","title":"Contraindications","mono":"<ul><li>concomitant use of strong CYP3A4 inducers (eg, carbamazepine)<\/li><li>hypersensitivity to delamanid or any component of the product<\/li><li>serum albumin less than 2.8 g\/dL<\/li><\/ul>"},{"id":"930951-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- avoid use if QTcF is greater than 500 msec prior to the first treatment dose<\/li><li>-- avoid use in patients with congenital QT prolongation, history of cardiac arrhythmia, clinically relevant bradycardia, or cardiac conditions that predispose arrhythmia (eg, severe hypertension, left ventricular hypertrophy including hypertrophic cardiomyopathy, congestive cardiac failure accompanied by  reduced left ventricle ejection fraction); monitor frequently if use is unavoidable<\/li><li>--QTc interval duration exceeds 450 msec for male or 470 msec for female during  treatment; monitoring recommended<\/li><li>-- QT prolongation slowly increases during the first 6 to 10 weeks of treatment; monitoring recommended; discontinue use if QTcF greater than 500 msec occurs<\/li><li>Endocrine and Metabolic:<\/li><li>-- avoid use in patients with electrolyte disturbances, especially hypokalemia, hypocalcemia or hypomagnesemia; monitor frequently if use is unavoidable<\/li><li>-- hypoalbuminemia (serum albumin falls below 3.4 g\/dL); increased risk of QT interval prolongation; monitoring recommended<\/li><li>-- patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption; contains lactose<\/li><li>Hepatic:<\/li><li>-- use not recommended in patients with moderate to severe hepatic impairment<\/li><li>Renal:<\/li><li>-- use not recommended in patients with severe renal impairment<\/li><li>Reproductive:<\/li><li>-- use not recommended during pregnancy<\/li><li>Concomitant use:<\/li><li>-- avoid concomitant use with antiarrhythmics (eg, amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine,  hydroquinidine, sotalol); neuroleptics (eg phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, thioridazine); antidepressives; strong inhibitor of CYP3A (eg, lopinavir\/ritonavir), certain antimicrobial agents (including macrolides (eg, erythromycin, clarithromycin), fluoroquinolones (eg, moxifloxacin, sparfloxacin), triazole antifungal agents, pentamidine, saquinavir); certain nonsedating antihistamines (eg, terfenadine, astemizole, mizolastine); and other certain QT prolonging drugs (ie, cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, or arsenic trioxide); increased risk of QT prolongation; monitor frequently if use is unavoidable<\/li><\/ul>"},{"id":"930951-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"930951-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930951-s-4","title":"Drug Interactions","sub":[{"id":"930951-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Dronedarone (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Mesoridazine (established)<\/li><li>Mitotane (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"930951-s-4-14","title":"Major","mono":"<ul><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Azithromycin (theoretical)<\/li><li>Bedaquiline (theoretical)<\/li><li>Boceprevir (probable)<\/li><li>Buserelin (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Cobicistat (probable)<\/li><li>Conivaptan (probable)<\/li><li>Crizotinib (theoretical)<\/li><li>Cyclobenzaprine (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delavirdine (probable)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (theoretical)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxepin (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Ebastine (theoretical)<\/li><li>Eribulin (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Famotidine (theoretical)<\/li><li>Felbamate (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Formoterol (theoretical)<\/li><li>Foscarnet (theoretical)<\/li><li>Galantamine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroquinidine (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imatinib (probable)<\/li><li>Imipramine (theoretical)<\/li><li>Indinavir (probable)<\/li><li>Itraconazole (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lopinavir (probable)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Mizolastine (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nefazodone (probable)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Pentamidine (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Perphenazine (theoretical)<\/li><li>Probucol (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Rilpivirine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (probable)<\/li><li>Sertindole (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tacrolimus (theoretical)<\/li><li>Tamoxifen (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telavancin (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Tipranavir (probable)<\/li><li>Tizanidine (theoretical)<\/li><li>Tolterodine (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilanterol (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vorinostat (theoretical)<\/li><\/ul>"}]},"5":{"id":"930951-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Palpitations (8.1%)<\/li><li><b>Endocrine metabolic:<\/b>Hyperuricemia (10% or greater), Hypokalemia (10% or greater)<\/li><li><b>Gastrointestinal:<\/b>Decrease in appetite (10% or greater), Diarrhea (10% or greater), Nausea (38.3%), Upper abdominal pain (10% or greater), Vomiting (33%)<\/li><li><b>Hematologic:<\/b>Reticulocytosis (10% or greater)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (10% or greater), Myalgia (10% or greater)<\/li><li><b>Neurologic:<\/b>Asthenia (10% or greater), Dizziness (30.2%), Headache (10% or greater), Insomnia (10% or greater), Paresthesia (10% or greater), Tremor (10% or greater)<\/li><li><b>Otic:<\/b>Tinnitus (10% or greater)<\/li><li><b>Respiratory:<\/b>Hemoptysis (10% or greater)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval (QTcF interval greater than 500 msec(0.3%); an increase in QTcF greater than 60 msec (3.7%); overall (9.9% or greater))<\/li><li><b>Other:<\/b>Drug resistance<\/li><\/ul>"},"6":{"id":"930951-s-6","title":"Drug Name Info","sub":{"2":{"id":"930951-s-6-19","title":"Class","mono":"<ul><li>Antitubercular<\/li><li>Nitroimidazole<\/li><\/ul>"},"3":{"id":"930951-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930951-s-7","title":"Mechanism Of Action","mono":"Delamanid is a antimycobacterial antibiotic that exerts its cytotoxic activity by inhibiting methoxy-mycolic and keto-mycolic acid synthesis. These are necessary components of the mycobacterial cell wall. <br\/>"},"8":{"id":"930951-s-8","title":"Pharmacokinetics","sub":[{"id":"930951-s-8-23","title":"Absorption","mono":"2.7-fold increased exposure with standard meal <br\/>"},{"id":"930951-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding, 99.5% or greater<\/li><li>Vd, approximately 2100 L<\/li><\/ul>"},{"id":"930951-s-8-25","title":"Metabolism","mono":"<ul><li>Plasma: primarily by albumin and to a lesser extent via CYP3A4<\/li><li>Metabolites: DM-6705, inactive<\/li><\/ul>"},{"id":"930951-s-8-26","title":"Excretion","mono":"<ul><li>Renal: Less than 5% unchanged<\/li><li>Dialyzable: Unknown (hemodialysis and peritoneal dialysis)<\/li><\/ul>"},{"id":"930951-s-8-27","title":"Elimination Half Life","mono":"30 to 38 hours <br\/>"}]},"9":{"id":"930951-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>take with food<\/li><li>administration by directly observed therapy (DOT) is recommended<\/li><\/ul>"},"10":{"id":"930951-s-10","title":"Monitoring","mono":"<ul><li>improvement in TB symptoms indicates efficacy<\/li><li>directly observed therapy is recommended<\/li><li>serum electrolytes; at baseline<\/li><li>ECG; prior to treatment and monthly while receiving treatment; more frequent monitoring if the QTc interval exceeds 500 msec before or during treatment, or 450 msec in women, or 470 msec in men and in patients with hypoalbuminemia, known congenital QT prolongation, history of cardiac arrhythmias, clinically relevant bradycardia, or conditions predisposing arrhythmia, or electrolyte disturbances, or concomitant use of agents known to prolong the QTc interval<\/li><\/ul>"},"13":{"id":"930951-s-13","title":"Clinical Teaching","mono":"<ul><li>Counsel women of childbearing potential to avoid pregnancy and breastfeeding during therapy.. Use of adequate contraception is recommended.<\/li><li>Warn patient that drug contains lactose monohydrate.<\/li><li>Side effects may include dizziness, headache, paresthesia, tremor, anorexia, insomnia, tinnitus, arthralgia, or myalgia.<\/li><li>Instruct patient to take drug with food.<\/li><li>Advise patient of the importance for completing the entire course of therapy<\/li><li>Advise patient that there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use, including over-the-counter and herbal drugs..<\/li><\/ul>"}}}